Speedy Service!
Low Prices!

Atropine Sulfate 1% Ophthalmic Ointment, 3.5 g
Prescription Required


Atropine Sulfate Ophthalmic Ointment 1% is a sterile ophthalmic ointment used for pupil dilation in the treatment of inflammatory conditions of the eye.

Out of stock


Atropine Sulfate Ophthalmic Ointment 1% is a sterile ophthalmic ointment used for pupil dilation in the treatment of inflammatory conditions of the eye. Made by Bausch and Lomb Incorporated.

Additional information

Weight .06 lbs
Dimensions 1.06 x 1.63 x 3.38 in

More Details

This medication requires a prescription from your veterinarian.

Atropine Sulfate Ophthalmic is available as a solution (drops) or ointment for use in humans.  Atropine Sulfate is used extra-label in veterinary patients for pupillary dilation desired in inflammatory conditions of the iris and uveal tract. Atropine sulfate plays an important role in controlling pain secondary to corneal and uveal disease. It is also used perioperatively to maximally dilate the pupil during intraocular surgery. Atropine has also been used to break down synechiae in uveitis.


Atropine Sulfate Ophthalmic Ointment, USP 1% is available in 3.5 gram ophthalmic tubes.



General recommendations- Initially, 1/8th inch strip in the affected eye(s) 2-3 times daily, and then once daily or every other day thereafter to achieve pupillary dilation.


  • Hypersalivation (drooling) can occur.
  • Use proper administration techniques to avoid contamination of the medication. Keep cap tightly closed when not in use.
  • Wait 5 minutes after applying atropine before applying any other medications to the eye.
  • Wash hands after use to prevent it affecting your eyes.

Adverse effects reported in humans or animals include sensitivity to bright light or sunlight, burning and irritation upon application, and in cats and dogs, decreased tear production and hypersalivation; ointment forms may avoid hypersalivation.

Atropine sulfate is contraindicated in patients with a history of hypersensitivity to it or any component of the formulation and should not be used in patients with primary glaucoma.

Ophthalmic atropine may induce colic in horses secondary to systemic absorption, but this is rarely reported.


Manufacturer Product Information

ATROPINE SULFATE- atropine sulfate ointment 
Bausch & Lomb Incorporated

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

Atropine Sulfate Ophthalmic Ointment USP, 1% (Sterile)
Rx only


 Atropine Sulfate Ophthalmic Ointment USP, 1% is a sterile topical anticholinergic for ophthalmic use. The active ingredient is represented by the chemical structural formula:

Mol. wt. 694.84

Chemical name:

Benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo-(3.2.1)oct-3-yl ester, endo-(±)-, sulfate (2:1) (salt), monohydrate.

Each Gram Contains:

Atropine Sulfate Ophthalmic Ointment USP, 1%, contains in each gram of ointment: ACTIVE: Atropine Sulfate USP, 1% (10mg); INACTIVES: White Petrolatum, Mineral Oil, Lanolin Oil and Purified Water.


The anticholinergic effect of this product blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia).


For mydriasis and/or cycloplegia. For cycloplegic refraction, for pupillary dilation desired in inflammatory conditions of the iris and uveal tract.


This product should not be used in patients with primary glaucoma or a predisposition to narrow anterior chamber angle glaucoma.

This product should not be used in pediatric patients who have previously had a severe systemic reaction to atropine. This product should not be used in those persons showing hypersensitivity to any component of this preparation.


In pediatric patients, use with extreme caution. Excessive use in pediatric patients or in certain individuals with a previous history of susceptibility to belladonna alkaloids may produce systemic symptoms of atropine poisoning. If this occurs, discontinue medication, and use appropriate therapy as outlined in “OVERDOSAGE” section.


To avoid excessive systemic absorption, the lacrimal sac should be compressed by digital pressure for two to three minutes after instillation. To avoid inducing angle closure glaucoma, an estimation of the depth of the angle of the anterior chamber should be made. Administration of atropine in infants requires great caution.

Patient Warning:

Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation.

Parents should be warned not to get this preparation in their children’s mouth and to wash their own hands and the child’s hands following administration.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

No studies have been conducted in animals or in humans to evaluate the potential of these effects.

Pregnancy Category C:

Animal reproduction studies have not been performed with atropine. It is also not known whether atropine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Atropine should be given to pregnant women only if clearly needed.

Pediatric Use:

See "WARNINGS" sections.


Prolonged use may produce local irritation characterized by follicular conjunctivitis, vascular congestion, edema, exudate, and an eczematoid dermatitis. Severe reactions are manifested by hypotension with progressive respiratory depression. Coma and death have been reported in the very young.


Systemic atropine toxicity is manifested by flushing and dryness of the skin (a rash may be present in pediatric patients),blurred vision, a rapid and irregular pulse, fever, abdominal distension in infants, mental aberration (hallucinosis) and loss of neuromuscular coordination.

Atropine poisoning, although distressing, is rarely fatal, even with large doses of atropine, and is self-limited if the cause is recognized and the atropine medication is discontinued. In severe intoxication, physostigmine salicylate may be administered parenterally to provide more prompt relief of the intoxication. Give physostigmine salicylate as 1-5 mL IV of dilution containing 1 mg in 5 mL of saline. The smaller dose is for pediatric patients, and injection should take not less than two minutes. EKG control is advisable. Dosage can be repeated every five minutes up to a total dose of 2 mg in pediatric patients and 6 mg in adults every 30 minutes. Physostigmine is contraindicated in hypotensive reactions. Atropine (1 mg) should be available for immediate injection if physostigmine causes bradycardia, convulsions or bronchoconstriction. In pediatric patients, the body surface must be kept moist.

Use extreme caution when employing short-acting barbiturates to control excitement.


ATROPINE SULFATE OINTMENT: A small amount in the conjunctival sac once or twice a day or as directed by a physician.



Atropine Sulfate Ophthalmic Ointment USP, 1% is supplied in an ophthalmic tip applicator tube in the following size:

3.5 gm tube - Prod. No. 05134


There are no reviews yet.

Be the first to review “Atropine Sulfate 1% Ophthalmic Ointment, 3.5 g”